Company Overview

Corcept Therapeutics Incorporated, incorporated in 1998 and headquartered in Redwood City, California, is a commercial-stage company dedicated to the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. For over 25 years, Corcept's specialized focus on cortisol modulation and its therapeutic potential across a wide array of serious diseases has led to the discovery of more than 1,000 proprietary selective cortisol modulators.

Core Business and Products

Primary Revenue Driver - Korlym®

The company's principal revenue stream comes from Korlym® tablets, a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who also have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery. Korlym® was introduced in February 2012, marking it as the first FDA-approved medication specifically for Cushing's syndrome patients.

Pipeline Development

Relacorilant - Lead Pipeline Asset

Corcept is actively developing relacorilant, its lead pipeline candidate. It is currently in:

- Phase III clinical trial for the treatment of hypercortisolism.

- Phase III clinical trial when combined with nab-paclitaxel, for the treatment of platinum-resistant ovarian tumors.

- Phase 1b clinical trial for the treatment of adrenal cancer and cortisol excess.

- Phase II clinical trial for the treatment of prostate cancer.

The relacorilant program has shown significant promise. The drug met its primary endpoint in the Phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, which led to a substantial surge in Corcept's stock price. Corcept plans to submit a new drug application (NDA) for relacorilant this quarter.

Additional Pipeline Assets

The company is also advancing other promising candidates:

- Dazucorilant: Currently in Phase II clinical trial for amyotrophic lateral sclerosis (ALS).

- Miricorilant: Undergoing Phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Recent Financial Performance

2024 Full-Year Results

- Revenue: $675.0 million (a 40% increase over 2023)

- Net Income: $141.2 million (a 33% increase over 2023)

Q3 2024 Performance

- Revenue: $182.5 million (up 48% year-over-year)

- Net Income: $47.2 million

- EPS: $0.41

- Corcept raised its 2024 revenue guidance to $675-700 million.

Q1 2025 Performance

- Revenue: $157.2 million (compared to $146.8 million in Q1 2024)

- Net Income per Common Share (Diluted): $0.17 (compared to $0.25 in Q1 2024)

Financial Position

- Cash and Investments: $603.2 million as of December 31, 2024.

Forward Guidance and Growth Outlook

Corcept Therapeutics has set its 2025 revenue guidance at $900 – $950 million, indicating strong growth expectations. To support the anticipated launch of relacorilant, which is projected to generate $3 billion to $5 billion in annual revenue, the company plans to expand its clinical specialist team to 175 by the end of the year.

Clinical Trial Progress and Market Recognition

GRACE and GRADIENT Studies

The GRADIENT trial demonstrated clinically meaningful improvements in patients with Cushing's syndrome, showing positive impacts on hypertension, hyperglycemia, weight, and body composition. In May 2024, Corcept announced that the GRACE study met its primary endpoint in the randomized withdrawal phase.

CATALYST Study Results

The CATALYST study revealed that approximately one in four patients with difficult-to-control diabetes have underlying hypercortisolism, and treatment significantly improved their hyperglycemia.

Market Position and Growth Drivers

There is increasing physician awareness regarding the prevalence of hypercortisolism and the poor health outcomes associated with untreated patients. This has led to more common screening practices and an increased number of patients receiving appropriate care.

Corcept has observed a robust growth trajectory in its hypercortisolism business, with a record rate of new prescriber base growth sustained for five consecutive quarters. Korlym® prescriptions nearly doubled compared to the previous year, even with a 13% decrease in average price per tablet due to the transition to an authorized generic.

With a market capitalization between $2 billion and $10 billion, CORT is positioned in the mid-capitalization segment.

Corcept Therapeutics represents a specialized pharmaceutical company demonstrating strong commercial execution in rare endocrine disorders. Its promising pipeline, focused on cortisol modulation across multiple therapeutic areas, coupled with expanding market recognition of hypercortisolism's impact, positions the company for continued growth in both existing and new therapeutic applications.